A real – life observational pilot study to evaluate the effects of two-week treatment with montelukast in patients with chronic cough

Mincheva, Roxana; Kralimarkova, Tanya; Rasheva, Miroslava; Dimitrov, Zlatko; Nedeva, Denislava; Staevska, Maria; Papochieva, Vera; Perenovska, Penka; Bacheva, Karina; Dimitrov, Vasil; Popov, Todor A.

doi:10.1186/1745-9974-10-2

Cited by 13 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study is similar to the work of Philip G et al, where marked improvement was observed in nasal and ocular symptoms after the two weeks treatment with montelukast 10 mg, the same study also concluded that this significant reduction in the symptoms of AR imposed a positive impact on asthma-related problems of the patient who were dealing with both the disorders. 14 Montelukast particularly has a positive impact on cough and all the discomforts associated with it, 15 and this is quite evident in our patients as well.…”

Section: Discussionsupporting

confidence: 63%

Role of Montelukast in Asthma and Allergic rhinitis patients

Zuberi¹,

Haroon

Haseeb³

et al. 2020

Pak J Med Sci

View full text Add to dashboard Cite

Objectives: Our objective was to evaluate the effect of Montelukast on the symptoms of asthma and allergic rhinitis (AR), assess its effect on the individual quality of life (QoL), and estimate the proportion of participants having adverse effects. Methods: This prospective, open-label study conducted at Dow University of Health Sciences, Ankle Saria Hospital and Sindh Government Hospital Liaquatabad, Karachi, from August 2018 to September 2019, included patients aged >18 years with a clinical diagnosis of Asthma, AR, or both. Patients were given a 10 mg Montelukast tablet each day and then called for follow-up in the fourth week, where the questions related to the improvement in the symptoms of asthma or AR were asked. Patients were also asked about the improvement in QoL and any adverse effects. Results: A total of 694 patients were registered of which 138(19.8%) had AR, 294(42.4%) had asthma, while 273(39.3%) had both. Mean age was 41.1±14.63 years and 352 (50.7%) were male and 342(49.3%) were females. On a follow-up visit, there was a sufficient improvement in 351 asthmatics (63.9%), and 288 patients with AR (70.1%) overall, strong or marked improvement in the day (n=342,62.3%) and night time (n=331,60.3%) asthma symptoms. Overall improvements in QoL were very good or good in 419 patients. Montelukast was well-tolerated here with adverse effects (like abdominal discomfort, fever, fatigue, headache, rash, and upper respiratory tract symptoms) seen in 125 patients (18.01%). Conclusion: Montelukast was very effective in improving the symptoms and QoL of the individuals suffering from asthma and/or AR. doi: https://doi.org/10.12669/pjms.36.7.2657 How to cite this:Zuberi FF, Haroon MA, Haseeb A, Khuhawar SM. Role of Montelukast in Asthma and Allergic rhinitis patients. Pak J Med Sci. 2020;36(7):---------. doi: https://doi.org/10.12669/pjms.36.7.2657 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Discussionsupporting

confidence: 63%

Role of Montelukast in Asthma and Allergic rhinitis patients

Zuberi¹,

Haroon

Haseeb³

et al. 2020

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…One prospective observational study reported that montelukast therapy for 2 weeks significantly improved symptoms of chronic cough. 31 However, the possibility of natural remission cannot be ruled out in an observational study lacking a control group. LTRAs were not effective in a RCT of 276 patients with subacute post-infectious cough, suggesting the lack of direct anti-tussive effects of LTRAs.…”

Section: Empirical Treatment For Non-specific Chronic Coughmentioning

confidence: 99%

KAAACI Evidence-Based Clinical Practice Guidelines for Chronic Cough in Adults and Children in Korea

Song

Kwon

et al. 2018

Allergy Asthma Immunol Res

View full text Add to dashboard Cite

Chronic cough is common in the community and causes significant morbidity. Several factors may underlie this problem, but comorbid conditions located at sensory nerve endings that regulate the cough reflex, including rhinitis, rhinosinusitis, asthma, eosinophilic bronchitis, and gastroesophageal reflux disease, are considered important. However, chronic cough is frequently non-specific and accompanied by not easily identifiable causes during the initial evaluation. Therefore, there are unmet needs for developing empirical treatment and practical diagnostic approaches that can be applied in primary clinics. Meanwhile, in referral clinics, a considerable proportion of adult patients with chronic cough are unexplained or refractory to conventional treatment. The present clinical practice guidelines aim to address major clinical questions regarding empirical treatment, practical diagnostic tools for non-specific chronic cough, and available therapeutic options for chronic wet cough in children and unexplained chronic cough in adults in Korea.

show abstract

“…Compared with individuals with no health-related dysfunction, it revealed that cough was associated with dysfunction in patients usual daily activities, particularly in the categories of ambulation, social interaction, sleep and rest, work, home management, and recreation [16]. According to a study done by Mincheva et al, in 2014, found that patients with chronic cough due to upper airway cough syndrome or gastroesophageal reflux disease but not asthma reported significant relief of their symptoms after 2 weeks of treatment with Montelukast [17].…”

Section: Discussionmentioning

confidence: 99%

The Efficacy and Prevalence of Montelukast Therapy in Cough-Variant Asthma Patients in Al-Kindy Teaching Hospital

Hamdan

2020

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Cough-variant asthma (CVA) is a type of asthma in which the main symptom is a dry, non-productive cough. OBJECTIVE: The objective of the study was to evaluate the therapeutic effect of Montelukast in CVA and to investigate the prevalence of Montelukast in CVA. METHODS: A cross-sectional study was conducted on 30 patients with chronic cough at least 8 weeks using Montelukast at Al-Kindy Hospital over the period of January 2018‒March 2018. An interview using questionnaire was used to collect the data that were specifically prepared to meet the objective of study including age, sex, associated disease, exacerbation factors, and classical therapy. RESULTS: There was a reduction of the symptoms associated with CVA after treatment with Montelukast. The prevalence of exacerbation factors was as follows: Dust (73.3%) of patients, food (36.7%), exercise (60%), psychological (56.7%), smoking (30%), and others (perfume and cold weather) (26.7%). The usage of Montelukast in this study was 73.3% (22 patients). Patients using Montelukast have shown improvement of symptoms as follows: Chest pain was relieved from 57.1% of patients, exhaustion (58.3%), vomiting (76.5%), sleep disturbance (54.5%), affecting daily life in 57.1%, and syncope 66.7%. CONCLUSION: The prevalence of Montelukast administration to the patients with chronic cough in our study was found to be more than 70% of the 30 total patients. Montelukast usage leads to reduction in the frequency of chronic cough and the symptoms associated with it.

show abstract

A real – life observational pilot study to evaluate the effects of two-week treatment with montelukast in patients with chronic cough

Cited by 13 publications

References 32 publications

Role of Montelukast in Asthma and Allergic rhinitis patients

Role of Montelukast in Asthma and Allergic rhinitis patients

KAAACI Evidence-Based Clinical Practice Guidelines for Chronic Cough in Adults and Children in Korea

The Efficacy and Prevalence of Montelukast Therapy in Cough-Variant Asthma Patients in Al-Kindy Teaching Hospital

Contact Info

Product

Resources

About